The production of recombinant proteins and antibodies requires specific biological and chemical agents and entails biological risks. As we know how much biosafety matters to our staff and clients, we’ve decided to train a Biological Safety Officer (BSO). Our BSO assists GTP’s technical leaders, assesses potential risks and is key to the implementation and continued application of a full-fledged biosafety policy.
Published on 2018-04-05 UpStream Process
Here, we provide a picture of the recent advances in mammalian cell line development and discuss the criteria a biotech company should consider when starting its cell line development process.
We have discussed antibody humanisation with Olivier Léger. He is an expert in antibody engineering with over 25 years' experience in the field.
Published on 2017-10-02 UpStream Process
Here we discuss about the feasibility to develop a CHO cell line based on retroviral vectors for therapeutic protein projects.
Published on 2017-06-12 Downstream Process
Here we discuss the reasons why a membrane chromatography step might be beneficial in your protein purification process.
Using continuous chromatography to improve process performance and debottleneck bioproduction capacity
Published on 2017-05-12 Downstream Process
In this article, Vincent Monchois, Director of Strategic Projects at Novasep, our CMO partner, explains why integration of continuous chromatography could help the biopharma industry overcome the challenges of increasing capacities and decreasing manufacturing costs.
Published on 2017-03-30 Analytics
In this third article of our series on QC, we are sharing our thoughts on the best way for biotech companies to address analytical development for characterisation of their biotherapeutic candidate at preclinical and clinical stages.
What methods to use for glycan characterisation of your antibody and protein products during process development?
Published on 2017-03-02 Analytics
In this second article of our series on QC development for biotherapeutics, our partner PROTEODYNAMICS, an expert company in glycan analysis and protein characterisation, gives a review of the relevant methods to characterise the glycosylation of your biotherapeutic candidates.
Published on 2017-01-25 Analytics
We are starting a series of articles addressing the question of QC development for biotherapeutic projects and have asked IDBiotech, which specialises in ELISA development, to explain why the quantification of HCPs is a key point to consider in CMC strategy.
We have tested the MEP HyperCel™ Chromatography Sorbent from Pall as a capture step for a polyclonal antibody
Published on 2016-10-13 Downstream Process
What you will read about: our evaluation of the MEP HyperCel™ sorbent as a non-protein A capture step for polyclonal antibodies